Georg Jaeschke,Fionn O'Hara,Jean-Marc Plancher,Antonio Ricci,Daniel Rueher,Eric Vieira,Fionn OHara
申请号：
US15867097
公开号：
US10011607B2
申请日:
2018.01.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to compounds of formula IwhereinR1 is hydrogen, F or Cl；L is a bond or lower alkylene；R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ═O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl； n is 1, 2 or 3；R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl；R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F；Y is CF or CCl；or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
